Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart.

This study compared the postprandial glycemic control achieved with meal-related insulin aspart injected immediately before a meal with that injected immediately after a meal.

Why It Was Studied

Patients with type 1 diabetes mellitus (DM) may encounter situations in which meal size and content is unpredictable.

Who Took Part

According to the abstract, 1, patients were involved.

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.

Adult patients with type 1 DM were enrolled.

At study visit 1, patients were randomly assigned to inject insulin aspart 0 to 5 minutes before the start of the meal or immediately after the meal.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

In the crossover set-up each of the patients took both Insulin Aspart and the comparison in turn, acting as their own control.

This randomized, crossover study was conducted at Sansum Diabetes Research Institute, Santa Barbara, California.

The timing of injection relative to the meal was reversed at study visit 2.

What Was Measured

The subject headings attached to it are Area Under Curve, Blood Glucose, Diabetes Mellitus, Type 1, Eating, Hypoglycemic Agents, Insulin and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Aspart in 1, patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2004 (Clinical therapeutics), a journal based in United States.

More context: the Insulin Aspart compound page, all human trials.